Are Connective Tissue Disorders Becoming More Common?
The available evidence does not directly address whether connective tissue disorders are increasing in prevalence—the provided guidelines focus on screening, diagnosis, and management rather than epidemiological trends. However, I can provide context based on what the evidence reveals about current disease burden and detection practices.
What the Evidence Actually Shows
Current Disease Burden
The evidence indicates that CTD-associated interstitial lung disease (ILD) represents a substantial subset, accounting for almost 20% of all ILDs 1. Within CTD-ILDs specifically:
- Systemic sclerosis-related ILD accounts for approximately 31% of CTD-ILDs
- Rheumatoid arthritis-related ILD accounts for approximately 39% of CTD-ILDs 1
The estimated prevalence of ILDs overall ranges between 72.1 and 164.2 cases per 100,000 Europeans 1, but this reflects all ILDs, not specifically CTDs.
Why Apparent Increases May Occur
Several factors could create the impression of increasing prevalence without actual disease increase:
Enhanced screening protocols: Recent guidelines (2024-2025) now recommend systematic screening for ILD in all patients with systemic sclerosis, rheumatoid arthritis, mixed connective tissue disease, Sjögren syndrome, idiopathic inflammatory myopathies, and systemic lupus erythematosus 2, 3. This represents a shift toward earlier and more comprehensive detection.
Improved diagnostic capabilities: The recognition that irreversible lung function loss can occur asymptomatically 1 has led to more aggressive screening, potentially identifying subclinical disease that would have been missed previously.
Better disease characterization: The 2025 Portuguese multidisciplinary consensus acknowledges that "the epidemiology of ILD in the context of connective tissue disease is difficult to determine due to undefined classification criteria, overlap syndromes, and undifferentiated CTD" 2.
Critical Caveats
The lack of epidemiological data in these recent guidelines is notable. All provided evidence from 2023-2025 focuses on:
- Screening recommendations
- Treatment protocols
- Organ involvement assessment
- Risk stratification
None directly address temporal trends in disease incidence or prevalence.
Clinical Implications
What This Means for Practice
You should maintain heightened vigilance for CTD diagnosis regardless of whether true prevalence is changing, because:
Early detection significantly impacts outcomes: CTD-ILD contributes to significant morbidity and early mortality 2
Progressive pulmonary fibrosis is the primary cause of death in CTD patients along with cardiovascular comorbidities 1
Systemic sclerosis remains the rheumatic disease with the highest morbidity and mortality despite recent survival improvements 4
The Real Question
Rather than asking if CTDs are becoming more common, the more clinically relevant question is: Are we detecting them earlier and more comprehensively? The answer to that is definitively yes, based on the proliferation of screening guidelines from 2023-2025 2, 1, 2, 3, 4.
Bottom Line
The provided evidence cannot answer whether CTD prevalence is truly increasing. What is clear is that:
- Detection methods have improved substantially
- Screening recommendations have become more comprehensive
- Recognition of subclinical disease is now standard practice
- Multidisciplinary approaches are now mandated
Any perceived increase in CTD cases may reflect improved case finding rather than true epidemiological change. To definitively answer your question would require population-based epidemiological studies examining incidence rates over time, which are not included in the provided evidence.